(Q34084265)

30 July 2017

1 reference

title

Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil (English)

1 reference

30 July 2017

1 reference

Paff MT

1

1 reference

30 July 2017

Baccanari DP

2

1 reference

30 July 2017

Davis ST

3

1 reference

30 July 2017

Cao S

4

1 reference

30 July 2017

Tansik RL

5

1 reference

30 July 2017

Rustum YM

6

1 reference

30 July 2017

Spector T

7

1 reference

30 July 2017

publication date

1 November 2000

1 reference

Investigational New Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

18

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

365-371

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1006401432488

30 July 2017

exact match

0 references

cites work

5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model

1 reference

12 December 2020

Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation

1 reference

12 December 2020

Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor

1 reference

12 December 2020

Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer

1 reference

12 December 2020

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil

1 reference

12 December 2020

Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine

1 reference

12 December 2020

Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration

1 reference

12 December 2020

5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil

1 reference

12 December 2020

A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients

1 reference

12 December 2020

Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy

1 reference

12 December 2020

Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer

1 reference

12 December 2020

The pharmacology of the fluoropyrimidines

1 reference

12 December 2020

Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid

1 reference

12 December 2020

A phase III study comparing the clinical utility of four regimens of 5-Fluorouracil.A preliminary report

1 reference

12 December 2020

Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients

1 reference

12 December 2020

5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs

1 reference

12 December 2020

5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules.

1 reference

12 December 2020

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

12 December 2020

In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation

1 reference

12 December 2020

Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients

1 reference

12 December 2020

Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil

1 reference

12 December 2020

Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors

1 reference

12 December 2020

Oral 5-fluorouracil in psoriasis: pharmacokinetic-pharmacodynamic relationships

1 reference

12 December 2020

Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil

1 reference

12 December 2020

(R)-5-fluoro-5,6-dihydrouracil: kinetics of oxidation by dihydropyrimidine dehydrogenase and hydrolysis by dihydropyrimidine aminohydrolase

1 reference

12 December 2020

Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile

1 reference

12 December 2020

Clinical development of eniluracil: current status

1 reference

12 December 2020

Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893).

1 reference

12 December 2020

Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate.

1 reference

12 December 2020

Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patients

1 reference

12 December 2020

Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil (Roche)

1 reference

12 December 2020

5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.

1 reference

12 December 2020

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity

1 reference

12 December 2020

The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster

1 reference

12 December 2020

Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infus

1 reference

12 December 2020

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

1 reference

12 December 2020

Enzymes of uracil catabolism in normal and neoplastic human tissues

1 reference

12 December 2020

Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients

1 reference

12 December 2020

Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells

1 reference

12 December 2020

Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate

1 reference

12 December 2020

Metabolism of pyrimidine analogues and their nucleosides

1 reference

12 December 2020

5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006401432488

1 reference

Dimensions Publication ID

30 July 2017

1052414804

0 references

1 reference